This is Part 4 of 5 in the “The Weight of Empire: Novo Nordisk’s Fight for Survival” series.
There is a peculiar feature of Danish corporate law that most investors never bother to understand until it costs them money. The Novo Nordisk Foundation owns 28% of the company’s shares. It controls 77% of the votes. This is not a bug. It is, depending on whom you ask, either the most enlightened governance structure in global pharma or the most elegant mechanism for the disenfranchisement of capital ever devised.
The Foundation was created in 1989, born from the same impulse that had shaped Danish capitalism for generations: the belief that certain institutions were too important to be left to the market. Its charter mandated two obligations – to maintain a stable basis for the commercial activities of Novo Nordisk, and to support scientific, humanitarian, and social purposes. For decades, those obligations coexisted without friction. The company grew. The Foundation funded hospitals, universities, the Novo Nordisk Prize, the Steno Diabetes Center, and dozens of research initiatives that made Denmark punching above its weight in global science. Everyone benefited. Everyone was satisfied.
But the charter had been written for a company worth tens of billions of kroner, not hundreds of billions. It had been written for a world where the biggest threat to long-term value was an activist hedge fund, not a U.S. president with an executive order and a seventy-eight percent approval rating. And it had been written on the assumption that the Foundation’s interests and the company’s interests would always align – an assumption that, in the winter of 2025, was collapsing under the weight of its own contradictions.
The math was simple, and it was devastating.
The Foundation’s philanthropic budget depended on dividends from Novo Nordisk. In the peak years – 2023, 2024 – those dividends had been enormous, funding an annual charitable spend that exceeded 10 billion Danish kroner. The Novo Nordisk Foundation had become, by some measures, the largest charitable foundation in Europe, its grants supporting everything from climate research to indigenous health programs to the renovation of Copenhagen’s Rigshospitalet.
Now the dividends were shrinking. Novo Nordisk’s stock price had dropped roughly fifty percent. Revenue was under pressure from the Trump administration’s price caps. Margins were compressed by the restructuring costs. And the 2026 outlook – which Doustdar’s team was preparing to release in February – would show a further decline that would make the current dividend level unsustainable.
For Sorensen, this created an impossible arithmetic. The Foundation could maintain its philanthropic commitments, which meant demanding higher dividends from a company that couldn’t afford them. Or it could reduce charitable spending, which meant betraying the mission that justified the Foundation’s existence and its 77% voting control. Every dollar the Foundation spent on science was a dollar not reinvested in the company. Every dollar reinvested in the company was a dollar not spent on the mission that made the Foundation more than a holding company.
This tension had always existed in theory. Now it existed on a spreadsheet, and the columns did not balance.
In the weeks following the shareholder meeting, a loose coalition of institutional investors began to form. They did not call themselves activists – the word carried connotations of American-style agitation that made the European fund managers uncomfortable. They called themselves “concerned shareholders,” which sounded more reasonable and was, in its way, more dangerous.
The group included representatives from pension funds in Norway, Sweden, and the Netherlands. It included two large UK-based asset managers. It included a Danish sovereign wealth vehicle whose mandate was, ironically, to invest in companies that exemplified good governance. Their combined holdings represented roughly twenty percent of Novo Nordisk’s economic value, which would have given them significant influence in any other company. At Novo Nordisk, it gave them exactly nothing.
They met – virtually at first, then in person at a hotel in Amsterdam chosen for its distance from both Copenhagen and London – to discuss their options. The conversation was careful, legalistic, and profoundly frustrated.
“We own the company,” said the Norwegian fund manager, a woman who had spent twenty years in institutional investment and was not accustomed to impotence. “By any normal measure of ownership, we own more of this company than the Foundation does. And yet we cannot appoint a single board member, cannot influence strategy, cannot block a decision that we believe is destroying value.”
“The dual-class structure is legal under Danish law,” the group’s legal advisor said. “Challenging it would require either a change in legislation or a successful argument under EU corporate governance principles that no court has yet accepted.”
“So our options are what? Write a letter?”
“Your options are to sell, to lobby the Danish government for legislative reform, or to build enough public pressure that the Foundation voluntarily reforms its governance.”
The room was quiet for a moment. Everyone understood what “voluntarily reforms” meant in the context of Lars Rebien Sorensen. It meant never.
David Moore had been Novo Nordisk’s head of U.S. operations for three years – long enough to build the commercial infrastructure that turned Ozempic into a cultural phenomenon and Wegovy into the fastest-growing pharmaceutical launch in American history. He was good at his job. He was also, by December 2025, exhausted by it.
The pricing concession had changed everything. Moore had spent his career selling premium pharmaceuticals to a market that, however grudgingly, accepted premium prices. The new reality – $350 for Wegovy, $149 for the oral formulation – required a fundamentally different kind of operation. Volume-based. Payer-focused. Less about selling drugs to doctors and more about negotiating market access with insurance companies, pharmacy benefit managers, and government programs.
Moore told Doustdar he was leaving on a Tuesday afternoon, in a call that was brief and surprisingly free of drama. “This isn’t the job I signed up for,” he said. “And you need someone who knows the payer world better than I do.”
Doustdar did not argue. He had already identified Moore’s replacement.
Jamie Miller arrived from UnitedHealth Group in January 2026. She was forty-six, had spent fifteen years navigating the labyrinth of American health insurance, and understood the relationship between pharmaceutical companies and payers with a specificity that most pharma executives lacked. She had been on the other side of the table – the side that decided which drugs got covered and at what price – and she knew the mechanics of that decision process the way an engineer knows the mechanics of a bridge.
Her first week was spent in meetings that lasted twelve hours a day. She reviewed every payer contract, every rebate agreement, every formulary position that Novo Nordisk held in the American market. At the end of the week, she sent Doustdar a memo that was eleven pages long and began with a sentence that captured both her directness and the scale of the challenge.
“The good news,” she wrote, “is that at $350, Wegovy is now affordable for most insured Americans. The bad news is that we have built our entire U.S. commercial infrastructure around a product that costs $1,349. Every system, every incentive, every sales strategy, every relationship with every health system in the country was designed for a premium-priced drug. We are not adjusting a price. We are rebuilding a business.”
Doustdar read Miller’s memo on a Saturday morning in his office, which he had taken to occupying even on weekends. The Bagsvaerd campus was quiet on Saturdays – eerily so, after the layoffs. The corridors that had once bustled with researchers and marketers and project managers were noticeably emptier. The cafeteria on the ground floor, which had served twelve hundred lunches a day at its peak, now served fewer than seven hundred.
He was thinking about Miller’s analysis when his phone buzzed. Sorensen.
“Mike, I’ve reviewed the oral formulation launch plan. I have concerns about the $149 price point.”
Doustdar closed his eyes briefly. He had expected this call. “It’s necessary, Lars. The market has moved. If we price the pill above $200, the PBMs won’t put us on preferred formulary. We lose the volume play entirely.”
“The Foundation board is concerned about margin compression. We are already facing a dividend reduction discussion that I would prefer to delay.”
“I understand the Foundation’s position. But if we price the pill to protect dividends, we lose the U.S. oral market to Lilly, and the dividend discussion becomes permanent.”
There was a pause. In that pause lived the entire structural tension of Novo Nordisk’s governance – the CEO, who ran the company, trying to convince the chairman, who controlled the Foundation that controlled the company, that the company’s interests required a decision that the Foundation’s interests opposed.
“Proceed with the launch at $149,” Sorensen said finally. “But I want weekly margin reports on the oral portfolio. And Mike – I want to be consulted before any further pricing decisions. Not informed. Consulted.”
“Understood.”
Doustdar hung up and sat very still. He had gotten what he wanted – the price point he needed for market access. But the terms of the agreement revealed something he had been trying not to acknowledge. He was not running this company. He was operating it, within parameters set by a man who sat in a different building, held a different title, and answered to a different set of obligations. The CEO of Novo Nordisk, in the most consequential period of the company’s history, needed permission to set the price of his own product.
The minority shareholders’ letter arrived at the Foundation’s offices on the second Monday of January. It was addressed to Sorensen personally, signed by representatives of seventeen institutional investors, and it was, by the standards of European corporate correspondence, extraordinarily blunt.
It called the dual chairmanship “an unprecedented concentration of authority that is inconsistent with international governance best practices.” It noted that since the board restructuring, there was “no independent mechanism for oversight of the Foundation’s exercise of its voting power.” It requested – the word “demanded” was avoided, but the intent was unmistakable – that Sorensen commit to a timeline for separating the board and Foundation chairmanships and to appointing a majority of genuinely independent directors.
Sorensen read the letter in his office, placed it on his desk, and drafted a response that was three paragraphs long. It acknowledged the shareholders’ concerns. It reiterated the Foundation’s commitment to long-term value creation. And it stated, in language that was cordial but utterly immovable, that the Foundation’s governance structure “reflects a time-tested model that has served the company and its stakeholders well for decades, and the Foundation sees no reason to alter it at this time.”
The letter was, in diplomatic terms, a polite refusal. In power terms, it was a reminder. You may own the economics. We own the votes. And in the Kingdom of Denmark, votes are what matter.
February came, and with it, the numbers Doustdar had been dreading.
The 2026 guidance call was scheduled for a Tuesday morning – early enough to catch the European markets at open, late enough for the Asian markets to have already digested the news. Doustdar’s team had been rehearsing the talking points for a week. The slides were clean, the language was careful, and every number had been reviewed by legal, finance, and communications.
The headline figure was a projected sales decline of five to thirteen percent for the full year. The range was deliberately wide – Doustdar’s CFO had argued for a narrower band, but Doustdar overruled him, reasoning that it was better to set expectations low and beat them than to promise precision and miss.
The market did not appreciate the nuance. The stock dropped 17% in a single session – the worst one-day decline in the company’s history. Analysts who had been cautiously optimistic revised their models downward. Cable news ran the stock chart alongside images of the Bagsvaerd campus. A Bloomberg headline captured the moment with characteristic economy: “Novo’s Weight Loss Drug Empire Faces Its Own Shrinkage.”
In the executive conference room on the top floor of the Bagsvaerd headquarters, Doustdar stood before his leadership team. The room had floor-to-ceiling windows that looked out over the campus – the research buildings, the parking structures, the remnants of the construction projects that had once symbolized infinite growth.
“This is the bottom,” he said. His voice was steady. His hands were at his sides. “This is the trough of the U. Everything we’ve done – the restructuring, the pricing adjustment, the commercial pivot – it takes time. The market doesn’t want to hear that. The market wants a quarter that looks like 2023. We’re not going to give them that. What we’re going to give them is a company that is positioned to grow again from a sustainable base. And when we do – when the volume plays in the U.S. and emerging markets start to show up in the numbers – the market will come back.”
He looked around the room. His chief financial officer was studying the table. His head of R&D was examining something on her phone. Jamie Miller, three weeks into her role, was watching Doustdar with an expression that was not hostile but was not reassuring either. Lars Rebien Sorensen was not present – he had taken the call from the Foundation offices – but his absence was, in its own way, a presence.
No one in the room believed him. Doustdar could see it in the way they held their bodies, in the micro-expressions that flashed across their faces before the professional masks reassembled. They had heard the U-shaped recovery speech before. They had seen the charts, the projections, the scenario models. And they had also seen the stock price cut in half, the board gutted, nine thousand colleagues shown the door, and a U.S. president dictate the price of their most important product.
Belief, Doustdar understood in that moment, was a commodity he had spent freely and could not easily replenish. The numbers would have to do the believing for him. And the numbers, for now, were silent.
This is a work of fiction. While inspired by real events and public information, all characters, dialogue, and internal deliberations are entirely imagined. Any resemblance to actual private conversations or decisions is coincidental.
